References
- Aouali N, Eddabra L, Macadre J, Morjani H. Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol 2005; 56: 61–70
- Friedenberg W R, Tallman M S, Brodsky I, Paietta E, Rowe J M, Lee S J, et al. Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group. Leuk Res 2004; 28: 813–819
- Matthews C, Catherwood M A, Larkin A M, Clynes M, Morris T CM, Alexander H D. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukaemia. Leuk Lymphoma 2006; 47(11)2308–2313
- Chiorazzi N, Rai K R, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815
- van der Holt B, Lowenberg B, Burnett A K, Knauf W U, Shepherd J, Piccaluga P P, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005; 106: 2646–2654
- Galski H, Sivan H, Lazarovici P, Nagler A. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: Implications on hematological malignancies. Leuk Res 2006; 30: 1151–1158
- Ganeshaguru K, Wickremasinghe R G, Jones D T, Gordon M, Hart S M, Virchis A E, et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 2002; 87: 167–176
- Szakacs G, Annereau J P, Lababidi S, Shankavaram U, Arciello A, Bussey K J, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6: 129–137